HIMS · Hims & Hers Health, Inc.
$28.15
-0.62 (-2.16%)
At close · Aug 14
Market Cap
$6.57B
Shares
233.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.15
Open$29.15
Day$28.11–29.30
52W close$14.52–62.76
Avg vol 30d14.1M
Short int62.2M · 26.7% float · 3.7d
Short vol64%
Last earningsAug 10, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−4%
below
Price vs 50-day avg
−11%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
28%
mid-range
Momentum
relative strength
1-month return
−14%
trailing
6-month return
+82%
trailing
YTD return
−13%
this year
Relative strength
+68%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $32 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +145 funds added
Insider flow
Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest
Rising
26.67% of float · ▲ +1.3% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
511 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+59%
Y/Y
Gross margin
74%
contracting
EPS growth
−4%
Y/Y
Buyback
$225.0M
remaining
Balance sheet
$228.6M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
third quarter 2026
Revenue
$880M – $900M
Adjusted EBITDA
Non-GAAP
$75M – $95M
full year 2026
Revenue
$3.1B – $3.3B
Adjusted EBITDA
Non-GAAP
$275M – $325M
Prior guidance
period ended
· from the 8-K filed May 11, 2026
Revenue
· second quarter 2026
$680M – $700M
Adjusted EBITDA
· second quarter 2026
$35M – $55M
Adjusted EBITDA margin
· second quarter 2026
5% – 8%
Guided vs delivered
· last 2 settled
Revenue
first quarter
guided $267M – $272M
$278.17M
Beat +3.2%
2025 guidance
2025
guided $1.2B
$2.35B
Beat +95.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−4%
Neutral
Price vs 50-day avg
−11%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
28%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $32 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +145 funds added
Insider flow
Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest
Rising
26.67% of float · ▲ +1.3% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
511 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $15
Now $28 · 28%
Range high $63
vs 200-day avg -4%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $60.3M | second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net (loss) income -86.29M
+47.5M Legal contingencies
+42.12M Stock-based compensation
+29.48M Depreciation and amortization
+28.84M Acquisition and transaction-related costs
+4.63M Restructuring and other related charges
+4.22M Change in fair value of liabilities
+2.02M Payroll tax expense related to stock-based compensation
+1.15M Impairment of long-lived assets
-2.25M Interest income and expense, net
-4.74M Change in fair value of equity securities
-6.34M (Benefit from) provision for income taxes
= Adjusted EBITDA 60.32M
|
|||
| Adjusted EBITDA margin non-GAAP | 8% | Three Months Ended June 30, 2026 | — |
| Free Cash Flow non-GAAP | -$68.2M | second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash (used in) provided by operating activities -35.94M
-25.93M Purchases of property, equipment, and intangible assets in investing activities
-6.33M Investment in website development and internal-use software in investing activities
= Free Cash Flow -68.19M
|
|||
| Monthly Revenue per Average Subscriber | $92 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Subscribers (end of period) | 2.89M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Monthly Online Revenue per Average Subscriber | $81 | Year Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HIMS
this stock
Hims & Hers Health, Inc.
|
$6.57B | -13.3% | +59.0% | — | 26.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$55.60B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.81B | +17.8% | +4.3% | 60.2 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HIMS | -10.9% | -14.3% | +81.5% | +1.4% | -13.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -11.3% | -18.7% | +67.7% | -2.6% | -27.2% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$250.00M
Spent (derived)
$25.00M
Remaining
$225.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1773751
CUSIP
433000106
13F (30d)
490 filings
484 filers
Visit website
Investor relations